Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed trust.
First of all, you or anyone else isn’t going to tell me who to follow or not, bucko! Second, you have a serious inability to “read between the lines”. So, maybe you should brush up on your skills there. Third, oh...you can spew chapter and verse of GDA guidelines but....your assumptions are all wrong. I’m not going any further than that. Good day!
Yeah, some of these people get a little bit of information and all of the sudden...they’re experts. Always looking for that “gotcha” moment. I’ve tried to be helpful to people on this blog and I come from a background with deep experience in PHARMA. I’m retired now but still know a lot about the FDA approval process. I’m just trying to help but some people just don’t get it.
Maybe instead of sending it to me....you might send it to Beplate....
I can’t get into why I was off on previous projections. Suffice it to say, I’m much more comfortable with my new estimates.....and I’ll leave it that.
Well, I guess we will see who’s right. It won’t be you!
I stand by my post.
You are incorrect on 2 fronts. First, companies who hare seeking approval do “not” generally provide updates to the approval process. The FDA frowns upon this and it could adversely affect the time to approval or the outcome. It’s just not done.
Beplate is taking the appropriate stance in keeping close to the vest on this and, in addition, you don’t want to give the competition or potential acquirers and advantage over the company.
Secondly, you are way off on your projection that approval is 180 days away.
Approval is near....I’m my opinion, I’m expecting it in the next few weeks. I speak from experience.
Personally, I feel as though it was one of those market maker frenzy of slapping the ask for several days. They sucked in investors with the “momentum trade”. I was looking at $2mm and didn’t take it off the table. My bad!
Agreed!
There’s only been 19k shares traded so, you can’t say that the market is showing some kinda wholesale dissatisfaction. There’s not that many shares traded. But, on the other hand, there isn’t anything in the 10-q that is making people hit the ask. The longtime shareholders are just waiting for the good stuff to come which, has to be soon. I’d say that this is a great buying opportunity.
Me too...
A quick answer would be “no” but I’m still reading.
10Q out.
Hopefully, we’ll be celebrating soon. Waiting is the hardest part.
Cheers buddy!
Nice pickup band aid!
I agree. My timeline for approval is before the end of August.
Concur!
Same to you and “thank you for your service”!
That is correct trust! You “have” been behind this from the beginning and you will be proven right. For me, the final deal maker was reading the clinical study. I’ve had my nose buried into clinical for 40 years. After reading the study design and the results I came to the conclusion that (barring any unforeseen blip) ....these results would definitely get the FDA class 3 approval. This kind of a study is as good as it gets in doing critical evaluations of HemoStyp. I applaud the company in presenting the medical world with this excellent piece of work!
GLTA!
Absolutely agree!
Why do you think that HemoStyp is being shelved by the FDA? I disagree. An FDA approval process is just that...a process. There are a lot of moving parts and there has been a brief delay due to Covid. I believe that we are close to approval. I’m looking at the end of July for that. You don’t just walk away from a product that beat SurgiCel “hands down” in our head to head trial. This approval will happen and ...I believe...it’s coming soon.
Take it from a PHARMA guy with 36 years of director level experience. This thing is the “real deal”!
Agreed trust. The first thing that companies do when they enter “talks” are to sign NDA’s. UEEC has the best hemostatic products and they are soon to be made available with the FDA approval. HemoStyp will become the “standard of care”! It’s only a matter of time and I think that time is about to unfold in the near term.
As “trust” has said “ this is a once in a lifetime investment”! I agree. The product is everything it’s being touted as and more. The company is creating more shareholder value by adding to a suite of HemoStyp off shoots. This will bring a better price for the company and I gotta think that however many companies are interested in buying UEEC will be paying more after the approval. You’d think that there is one smart company who sees this multi-billion dollar suite of products as a huge revenue producer for them yet, I’m surprised that no one (that we are aware of) has made any offer. Beplate has stated on a few occasions that they are in talks. I’m thinking that Beplate hasn’t seen an offer that acceptable yet. I really believe that we are close to approval. Maybe by July we will all be celebrating.
GLTA!
My vote for the worst post of the year! You don’t know what you’re talking about! Sell and go away!
I saw it. I’m not concerned that they “won’t” get the approval. I think a lot of the legal ease is just corporate CYA...nothing more.
I hear you. We gotta be close, though. Have a great weekend!
Hey “trust”...haven’t seen anything from you lately. Share some of your thoughts!
I don’t think so. That came out 5 days ago. If the drop in price is related to that then these people are really slow and the 8k was just more standard legal ease CYA. Nothing important and they also relayed that the 10k will be late. They are late every quarter. No big deal. This is just another buying opportunity.
Nah COL Mustard in the kitchen with a 9mm! HA!
Interesting...the way it was written leads me to believe that it could be “trusttheman”. If it was you “trust” nice job!
I can only guess but I’m thinking that the buys are “slapping the ask” which would have the tendency to keep the price up. I’d be interested in opinions from others. I’m more of a clinical guy.
Yeah, that makes sense. Can’t be too safe these days. My new estimate for approval is the end of June. If we’re not bought before approval then I can see a few companies throwing out offers. I believe the full potential of the suite of products is extraordinary. I’m with trust thinking that we could be looking at $20+ a share. Hey, if I’m wrong and it’s less than that, I will still be happy.
Hey band aid, if you unload before the buyout, you’re gonna leave a lot of money on the table. I’m waiting for a bidding war to unfold after approval.
The article was written by JcMarketman.
Good luck.
No, yesterday’s article is from a different author.
Welcome to the “go big club” Jimmy. I find it ironic that the Seeking Alpha article published yesterday is positive and the negative one that was published by ...White Diamond Research landed them a lawsuit. I guess the lesson learned is that you have to do your own DD. We should get a pop in the stock on the new article.
One other thing....I know all of you are thinking that this PR was nothing special. A lot of you know my past life in PHARMA.
I can say with strong conviction that, to me, they are soft-peddling anything they send out for public consumption. Why...
because they don’t want to jeopardize the approval with any “cart before the horse” press releases. They are laying low until the approval. This is a smart move since, in my opinion, they may very well be close to the approval.
Off my soapbox!
Ok, so my take on this pr are two things. One, the “pause” is off and they continue to move towards approval. Secondly, they have expanded the “suite” of products into
the dialysis market. It’s all good and I would expect that we must be getting close to approval. Just my take...
Two words Chris...”economic uncertainty”!